Smart scans may slash radiation doses for metastatic prostate cancer

NCT ID NCT07674771

First seen Jun 30, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase trial explores whether PSMA PET scans can help doctors adjust radiation therapy for men with prostate cancer that has spread to 4 to 20 spots in the body. Participants receive standard hormone therapy plus a special PET scan, then targeted radiation to all visible tumors. A repeat scan after three radiation sessions may allow some tumors to skip the final two sessions if they show a complete response. The goal is to see if this adaptive approach can safely reduce the total radiation dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
68Ga-PSMA-11 and adaptive stereotactic ablative radiotherapy (SABR)
What this could lead to
If successful, this approach could reduce the amount of radiation needed for each tumor site, potentially lowering side effects while maintaining cancer control.
What could go wrong
This is a very early-phase trial with only 30 participants, so results may not apply broadly. The imaging and radiation technique may not shrink tumors as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADAPTIVE RADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.